Biomolecules,
Год журнала:
2023,
Номер
13(3), С. 560 - 560
Опубликована: Март 20, 2023
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
currently
the
most
common
cause
of
chronic
worldwide.
Early
identification
and
prompt
treatment
are
critical
to
optimize
patient
management
improve
long-term
prognosis.
Long
non-coding
RNA
(lncRNA)
circular
(circRNA)
recently
emerging
RNAs,
highly
stable
easily
detected
in
circulation,
representing
a
promising
non-invasive
approach
for
predicting
NAFLD.
A
literature
search
Pubmed,
Embase,
Web
Science,
Cochrane
Library
databases
was
performed
36
eligible
studies
were
retrieved,
including
18
on
NAFLD,
13
nonalcoholic
steatohepatitis
(NASH),
11
fibrosis
and/or
cirrhosis.
Dynamic
changes
lncRNA
expression
associated
with
occurrence
progression
among
which
NEAT1,
MEG3,
MALAT1
exhibited
great
potential
as
biomarkers
Moreover,
mitochondria-located
circRNA
SCAR
can
drive
metaflammation
its
inhibition
might
be
therapeutic
target
NASH.
In
this
systematic
review,
we
highlight
lncRNA/circRNA
early
diagnosis
assessment
To
further
verify
their
clinical
value,
large-cohort
incorporating
both
tissue
blood
should
conducted.
Additionally,
detailed
functional
mechanisms
will
essential
elucidating
roles
diagnosing
treating
NASH,
fibrosis.
Gut,
Год журнала:
2024,
Номер
unknown, С. gutjnl - 330595
Опубликована: Янв. 16, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
has
rapidly
become
the
most
common
chronic
globally
and
is
currently
estimated
to
affect
up
38%
of
global
adult
population.
NAFLD
a
multisystem
where
systemic
insulin
resistance
related
metabolic
dysfunction
play
pathogenic
role
in
development
its
relevant
liver-related
morbidities
(cirrhosis,
failure
hepatocellular
carcinoma)
extrahepatic
complications,
such
as
cardiovascular
(CVD),
type
2
diabetes
mellitus,
kidney
disease,
certain
types
cancers.
In
2023,
three
large
multinational
associations
proposed
that
dysfunction-associated
steatotic
(MASLD)
should
replace
term
NAFLD;
name
chosen
non-alcoholic
steatohepatitis
was
(MASH).
Emerging
epidemiological
evidence
suggests
an
excellent
concordance
rate
between
MASLD
definitions—that
is,
~99%
individuals
with
meet
criteria.
this
narrative
review,
we
provide
overview
literature
on
(a)
recent
data
risk
developing
CVD
malignant
(b)
underlying
mechanisms
by
which
(and
factors
strongly
linked
MASLD)
may
increase
these
complications
(c)
diagnosis
assessment
potential
treatments
reduce
people
or
MASH.
BioScience Trends,
Год журнала:
2022,
Номер
16(1), С. 20 - 30
Опубликована: Фев. 23, 2022
Hepatocellular
carcinoma
(HCC)
is
the
fifth
most
common
malignancy
and
second
leading
cause
of
cancer-related
mortality
worldwide.
This
review
an
updated
version
that
summarizes
comprehensive
guidelines
published
from
January
2001
to
2022
worldwide
with
a
focus
on
clinical
management
HCC.
The
electronic
databases
MEDLINE,
Chinese
SinoMed,
Japanese
CiNii
were
systematically
searched.
A
total
22
characteristic
for
HCC
ultimately
included,
including
1
international
guideline,
11
Asia,
5
Europe,
4
America,
Australia.
If
in
multiple
versions,
recent
update
was
surveillance,
diagnosis,
treatment
compared.
composition
recommendations
current
varied,
so
these
regrouped
diagnostic
algorithms
summarized
graphically
provide
latest
information
clinicians.
criteria
grouped
into
2
categories:
"Size-based
pathway"
"Non-size-based
pathway".
according
different
algorithms,
mainstream
options
reviewed.
Findings
comparison
might
help
target
concentrate
efforts
improve
However,
further
studies
are
needed
outcomes
More
straightforward
or
refined
would
guide
doctors
make
better
decisions
future.
Journal of Hepatology,
Год журнала:
2023,
Номер
79(6), С. 1352 - 1365
Опубликована: Июль 17, 2023
Recent
studies
have
highlighted
the
role
of
gut
microbiota
and
their
metabolites
in
non-alcoholic
fatty
liver
disease-associated
hepatocellular
carcinoma
(NAFLD-HCC).
We
aimed
to
identify
specific
beneficial
bacterial
species
that
could
be
used
prophylactically
prevent
NAFLD-HCC.
Obesity Facts,
Год журнала:
2024,
Номер
17(4), С. 374 - 444
Опубликована: Янв. 1, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
termed
non-alcoholic
fatty
(NAFLD),
is
defined
as
(SLD)
in
the
presence
of
one
or
more
cardiometabolic
risk
factor(s)
and
absence
harmful
alcohol
intake.
The
spectrum
MASLD
includes
steatosis,
metabolic
steatohepatitis
(MASH,
NASH),
fibrosis,
cirrhosis
MASH-related
hepatocellular
carcinoma
(HCC).
This
joint
EASL-EASD-EASO
guideline
provides
an
update
on
definitions,
prevention,
screening,
diagnosis
treatment
for
MASLD.
Case-finding
strategies
with
using
non-invasive
tests,
should
be
applied
individuals
factors,
abnormal
enzymes,
and/or
radiological
signs
hepatic
particularly
type
2
diabetes
(T2D)
obesity
additional
factor(s).
A
stepwise
approach
blood-based
scores
(such
FIB-4)
and,
sequentially,
imaging
techniques
transient
elastography)
suitable
to
rule-out/in
advanced
which
predictive
liver-related
outcomes.
In
adults
MASLD,
lifestyle
modification
-
including
weight
loss,
dietary
changes,
physical
exercise
discouraging
consumption
well
optimal
management
comorbidities
use
incretin-based
therapies
(e.g.
semaglutide,
tirzepatide)
T2D
obesity,
if
indicated
advised.
Bariatric
surgery
also
option
obesity.
If
locally
approved
dependent
label,
non-cirrhotic
MASH
significant
fibrosis
(stage
≥2)
considered
a
MASH-targeted
resmetirom,
demonstrated
histological
effectiveness
acceptable
safety
tolerability
profile.
No
pharmacotherapy
can
currently
recommended
cirrhotic
stage.
Management
adaptations
drugs,
nutritional
counselling,
surveillance
portal
hypertension
HCC,
transplantation
decompensated
cirrhosis.
Liver
cancer
is
the
third
leading
cause
of
cancer-related
deaths
and
ranks
as
sixth
most
prevalent
type
globally.
NAFLD
or
metabolic
dysfunction-associated
steatotic
liver
disease,
its
more
severe
manifestation,
NASH
steatohepatitis
(MASH),
pose
a
significant
global
health
concern,
affecting
approximately
20%-25%
population.
The
increased
prevalence
disease
MASH
parallel
to
increasing
rates
obesity-associated
diseases,
including
2
diabetes,
insulin
resistance,
fatty
diseases.
can
progress
MASH-related
HCC
(MASH-HCC)
in
about
2%
cases
each
year,
influenced
by
various
factors
such
genetic
mutations,
carcinogen
exposure,
immune
microenvironment,
microbiome.
MASH-HCC
exhibits
distinct
molecular
characteristics
compared
other
causes
affects
both
men
women
equally.
management
early
intermediate-stage
typically
involves
surgery
locoregional
therapies,
while
advanced
treated
with
systemic
anti-angiogenic
therapies
checkpoint
inhibitors.
In
this
comprehensive
review,
we
consolidate
previous
research
findings
also
providing
current
insights
into
intricate
processes
underlying
development.
We
delve
MASH-HCC-associated
variations
somatic
progression
models,
multiomics
analysis,
immunological
microenvironmental
impacts,
discuss
targeted/combined
overcome
evasion
biomarkers
recognize
treatment
responders.
By
furthering
our
comprehension
mechanisms
MASH-HCC,
goal
catalyze
advancement
potent
strategies,
ultimately
enhanced
patient
outcomes.
